Sernova Corp. (SEOVF)
USD 0.15
(2.67%)
USD 0.15
(2.67%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | -8.58 Million CAD | -145.3% |
| 2022 | -3.5 Million CAD | 87.26% |
| 2021 | -27.48 Million CAD | -746.4% |
| 2020 | -3.24 Million CAD | -80.67% |
| 2019 | -1.79 Million CAD | -3.32% |
| 2018 | -1.73 Million CAD | 33.8% |
| 2017 | -2.62 Million CAD | 49.47% |
| 2016 | -5.19 Million CAD | -2353.29% |
| 2015 | -211.93 Thousand CAD | 54.3% |
| 2014 | -463.8 Thousand CAD | -69.52% |
| 2013 | -273.6 Thousand CAD | -7.06% |
| 2012 | -255.55 Thousand CAD | 17.56% |
| 2011 | -309.99 Thousand CAD | 57.83% |
| 2010 | -735.14 Thousand CAD | -85.19% |
| 2009 | -396.96 Thousand CAD | 13.96% |
| 2008 | -461.34 Thousand CAD | 74.37% |
| 2007 | -1.8 Million CAD | 37.38% |
| 2006 | -2.87 Million CAD | -902.74% |
| 2005 | -286.68 Thousand CAD | -54.51% |
| 2004 | -185.54 Thousand CAD | -43.84% |
| 2003 | -128.99 Thousand CAD | 62.27% |
| 2002 | -341.93 Thousand CAD | 78.38% |
| 2001 | -1.58 Million CAD | -9.47% |
| 2000 | -1.44 Million CAD | -259.96% |
| 1999 | -401.26 Thousand CAD | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q3 | -4.42 Million CAD | -56.76% |
| 2024 Q1 | -5.87 Million CAD | 31.57% |
| 2024 Q2 | -2.82 Million CAD | 51.93% |
| 2023 Q4 | -8.58 Million CAD | 51.23% |
| 2023 Q1 | -22.25 Million CAD | -535.75% |
| 2023 Q3 | -17.6 Million CAD | -41.14% |
| 2023 Q2 | -12.47 Million CAD | 43.95% |
| 2023 FY | -8.58 Million CAD | -145.3% |
| 2022 Q4 | -3.5 Million CAD | -29.13% |
| 2022 Q1 | -26.81 Million CAD | 2.43% |
| 2022 FY | -3.5 Million CAD | 87.26% |
| 2022 Q2 | -23.9 Million CAD | 10.86% |
| 2022 Q3 | -2.71 Million CAD | 88.66% |
| 2021 Q4 | -27.48 Million CAD | 8.05% |
| 2021 Q2 | -31.04 Million CAD | -239.99% |
| 2021 FY | -27.48 Million CAD | -746.4% |
| 2021 Q1 | -9.13 Million CAD | -181.26% |
| 2021 Q3 | -29.88 Million CAD | 3.74% |
| 2020 Q2 | -389.56 Thousand CAD | 55.34% |
| 2020 FY | -3.24 Million CAD | -80.67% |
| 2020 Q1 | -872.19 Thousand CAD | 51.47% |
| 2020 Q3 | -88.38 Thousand CAD | 77.31% |
| 2020 Q4 | -3.24 Million CAD | -3573.68% |
| 2019 FY | -1.79 Million CAD | -3.32% |
| 2019 Q4 | -1.79 Million CAD | -296.19% |
| 2019 Q3 | -453.6 Thousand CAD | 25.76% |
| 2019 Q2 | -611.02 Thousand CAD | 49.32% |
| 2019 Q1 | -1.2 Million CAD | 30.69% |
| 2018 Q1 | -2.28 Million CAD | 13.17% |
| 2018 Q3 | -2.19 Million CAD | -59.17% |
| 2018 Q4 | -1.73 Million CAD | 20.91% |
| 2018 FY | -1.73 Million CAD | 33.8% |
| 2018 Q2 | -1.38 Million CAD | 39.44% |
| 2017 Q2 | -5.31 Million CAD | -0.16% |
| 2017 Q4 | -2.62 Million CAD | 29.66% |
| 2017 FY | -2.62 Million CAD | 49.47% |
| 2017 Q1 | -5.3 Million CAD | -2.04% |
| 2017 Q3 | -3.73 Million CAD | 29.7% |
| 2016 Q2 | -2.89 Million CAD | -163.2% |
| 2016 FY | -5.19 Million CAD | -2353.29% |
| 2016 Q1 | -1.1 Million CAD | -419.31% |
| 2016 Q4 | -5.19 Million CAD | -4.29% |
| 2016 Q3 | -4.98 Million CAD | -72.11% |
| 2015 Q3 | -193.91 Thousand CAD | -30.38% |
| 2015 Q1 | -401.27 Thousand CAD | 13.48% |
| 2015 Q2 | -148.72 Thousand CAD | 62.94% |
| 2015 FY | -211.93 Thousand CAD | 54.3% |
| 2015 Q4 | -211.93 Thousand CAD | -9.3% |
| 2014 Q2 | -166.4 Thousand CAD | 24.77% |
| 2014 FY | -463.8 Thousand CAD | -69.52% |
| 2014 Q3 | -433.71 Thousand CAD | -160.63% |
| 2014 Q4 | -463.8 Thousand CAD | -6.94% |
| 2014 Q1 | -221.2 Thousand CAD | 19.15% |
| 2013 Q4 | -273.6 Thousand CAD | -17.14% |
| 2013 Q3 | -233.56 Thousand CAD | -156.71% |
| 2013 Q2 | -90.98 Thousand CAD | 82.67% |
| 2013 Q1 | -524.87 Thousand CAD | -105.39% |
| 2013 FY | -273.6 Thousand CAD | -7.06% |
| 2012 FY | -255.55 Thousand CAD | 17.56% |
| 2012 Q2 | -328.83 Thousand CAD | -186.14% |
| 2012 Q4 | -255.55 Thousand CAD | -56.29% |
| 2012 Q3 | -163.51 Thousand CAD | 50.27% |
| 2012 Q1 | -114.92 Thousand CAD | 62.93% |
| 2011 FY | -309.99 Thousand CAD | 57.83% |
| 2011 Q1 | -1.06 Million CAD | -45.47% |
| 2011 Q2 | -816.02 Thousand CAD | 23.7% |
| 2011 Q3 | -1.45 Million CAD | -78.37% |
| 2011 Q4 | -309.99 Thousand CAD | 78.7% |
| 2010 FY | -735.14 Thousand CAD | -85.19% |
| 2010 Q1 | -196.86 Thousand CAD | 50.41% |
| 2010 Q2 | -373.12 Thousand CAD | -89.53% |
| 2010 Q4 | -735.14 Thousand CAD | -59.19% |
| 2010 Q3 | -461.8 Thousand CAD | -23.77% |
| 2009 Q1 | -326.05 Thousand CAD | 29.33% |
| 2009 Q4 | -396.96 Thousand CAD | -6.36% |
| 2009 Q3 | -373.22 Thousand CAD | -148.31% |
| 2009 FY | -396.96 Thousand CAD | 13.96% |
| 2009 Q2 | -150.3 Thousand CAD | 53.9% |
| 2008 Q4 | -461.34 Thousand CAD | 35.27% |
| 2008 Q3 | -712.69 Thousand CAD | 30.02% |
| 2008 Q2 | -1.01 Million CAD | 26.84% |
| 2008 Q1 | -1.39 Million CAD | 22.67% |
| 2008 FY | -461.34 Thousand CAD | 74.37% |
| 2007 Q3 | -2.01 Million CAD | -9.34% |
| 2007 Q1 | -2.45 Million CAD | 14.68% |
| 2007 Q4 | -1.8 Million CAD | 10.71% |
| 2007 FY | -1.8 Million CAD | 37.38% |
| 2007 Q2 | -1.84 Million CAD | 24.82% |
| 2006 Q3 | -3.17 Million CAD | -646.93% |
| 2006 Q4 | -2.87 Million CAD | 9.51% |
| 2006 FY | -2.87 Million CAD | -902.74% |
| 2006 Q1 | -232.63 Thousand CAD | 18.86% |
| 2006 Q2 | -425.34 Thousand CAD | -82.84% |
| 2005 Q1 | -190.84 Thousand CAD | -2.86% |
| 2005 Q2 | -29.67 Thousand CAD | 84.45% |
| 2005 FY | -286.68 Thousand CAD | -54.51% |
| 2005 Q3 | -433.77 Thousand CAD | -1361.83% |
| 2005 Q4 | -286.68 Thousand CAD | 33.91% |
| 2004 Q4 | -185.54 Thousand CAD | -1040.65% |
| 2004 Q2 | 186.67 Thousand CAD | 386.93% |
| 2004 FY | -185.54 Thousand CAD | -43.84% |
| 2004 Q1 | -65.05 Thousand CAD | 49.57% |
| 2004 Q3 | 19.72 Thousand CAD | -89.43% |
| 2003 Q4 | -128.99 Thousand CAD | 54.29% |
| 2003 Q1 | -550.95 Thousand CAD | -61.13% |
| 2003 Q3 | -282.18 Thousand CAD | 6.25% |
| 2003 FY | -128.99 Thousand CAD | 62.27% |
| 2003 Q2 | -300.99 Thousand CAD | 45.37% |
| 2002 Q2 | -495.2 Thousand CAD | 52.86% |
| 2002 Q3 | -195.15 Thousand CAD | 60.59% |
| 2002 Q4 | -341.93 Thousand CAD | -75.21% |
| 2002 Q1 | -1.05 Million CAD | 0.0% |
| 2002 FY | -341.93 Thousand CAD | 78.38% |
| 2001 FY | -1.58 Million CAD | -9.47% |
| 2000 FY | -1.44 Million CAD | -259.96% |
| 1999 FY | -401.26 Thousand CAD | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Qrons Inc. | 351.42 Thousand USD | 2543.1% |
| Santhera Pharmaceuticals Holding AG | -6.3 Million USD | -36.183% |
| Nascent Biotech, Inc. | -249.62 Thousand USD | -3339.513% |
| Adynxx, Inc. | - USD | Infinity% |
| Acro Biomedical Co., Ltd. | 19.86 Thousand USD | 43315.946% |
| Capstone Therapeutics Corp. | 20.27 Million USD | 142.344% |
| BioStem Technologies, Inc. | 4.47 Million USD | 291.988% |
| CSL Limited | 10.52 Billion USD | 100.082% |
| Arch Therapeutics, Inc. | 5.64 Million USD | 252.003% |
| Evofem Biosciences, Inc. | 42.79 Million USD | 120.063% |
| Northwest Biotherapeutics, Inc. | 43.43 Million USD | 119.767% |
| Regen BioPharma, Inc. | 635.16 Thousand USD | 1451.725% |
| Skye Bioscience, Inc. | -5.72 Million USD | -50.063% |
| ProtoKinetix, Incorporated | -20.4 Thousand USD | -41970.325% |
| Rebus Holdings, Inc. | 305 Thousand USD | 2914.988% |
| Burzynski Research Institute, Inc. | -1310.00 USD | -655297.863% |
| Neon Bloom, Inc. | 622.36 Thousand USD | 1479.532% |
| Eiger BioPharmaceuticals, Inc. | 15.76 Million USD | 154.467% |
| Nanobac Pharmaceuticals, Incorporated | 4.11 Million USD | 308.491% |
| Institute of Biomedical Research Corp. | 401.84 Thousand USD | 2236.552% |
| SQZ Biotechnologies Company | -36.23 Million USD | 76.307% |
| Intellipharmaceutics International Inc. | 2.24 Million USD | 482.909% |
| Propanc Biopharma, Inc. | 927.18 Thousand USD | 1025.997% |
| Mesoblast Limited | 55.85 Million USD | 115.371% |
| Marizyme, Inc. | 18.56 Million USD | 146.237% |
| Genus plc | 190.6 Million USD | 104.505% |
| VioQuest Pharmaceuticals, Inc. | 2.23 Million USD | 484.005% |
| Pharming Group N.V. | 109.8 Million USD | 107.819% |
| Therapeutic Solutions International, Inc. | 860.24 Thousand USD | 1098.059% |
| CNBX Pharmaceuticals Inc. | 1.21 Million USD | 807.29% |
| Nymox Pharmaceutical Corporation | 680 Thousand USD | 1362.605% |
| ContraFect Corporation | -6.02 Million USD | -42.478% |
| PsyBio Therapeutics Corp. | 134.63 Thousand USD | 6476.839% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 1.15 Million USD | 843.076% |
| IMV Inc. | 7.67 Million USD | 211.931% |
| AXIM Biotechnologies, Inc. | 5.5 Million USD | 256.05% |
| MultiCell Technologies, Inc. | 90.04 USD | 9535542.026% |
| ONE Bio Corp. | 9.04 Million USD | 194.974% |
| Accustem Sciences Inc. | -733.97 Thousand USD | -1069.751% |
| RVL Pharmaceuticals plc | 12.94 Million USD | 166.319% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| EV Biologics, Inc. | 1.36 Million USD | 727.624% |
| Q BioMed Inc. | 4.06 Million USD | 311.47% |
| Emmaus Life Sciences, Inc. | 30.55 Million USD | 128.1% |
| Mosaic ImmunoEngineering Inc. | 1 Million USD | 951.997% |
| Biomind Labs Inc. | 711.4 Thousand USD | 1306.872% |
| American Oriental Bioengineering, Inc. | 60.54 Million USD | 114.181% |
| Provectus Biopharmaceuticals, Inc. | 1.99 Million USD | 529.416% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| Oncotelic Therapeutics, Inc. | 12.8 Million USD | 167.041% |
| GlobeStar Therapeutics Corporation | 359.71 Thousand USD | 2486.843% |
| THC Farmaceuticals, Inc. | 139.8 Thousand USD | 6241.249% |
| Curative Biotechnology, Inc. | 2.2 Million USD | 489.909% |
| GB Sciences, Inc. | 1.74 Million USD | 591.366% |
| Alpha Cognition Inc. | -183.78 Thousand USD | -4571.53% |
| HST Global, Inc. | 96.79 Thousand USD | 8970.179% |
| Wesana Health Holdings Inc. | 206.21 Thousand USD | 4263.436% |
| Halberd Corporation | 144.72 Thousand USD | 6032.596% |
| Enzolytics Inc. | 981.65 Thousand USD | 974.615% |
| Agentix Corp. | 37.63 Thousand USD | 22915.53% |
| Resverlogix Corp. | 6.45 Million USD | 233.091% |
| Nuo Therapeutics, Inc. | -673.08 Thousand USD | -1175.569% |
| MetaStat, Inc. | - USD | Infinity% |
| argenx SE | -2.02 Billion USD | 99.577% |
| Enzon Pharmaceuticals, Inc. | -47.01 Million USD | 81.737% |
| Endonovo Therapeutics, Inc. | 7.07 Million USD | 221.422% |
| RespireRx Pharmaceuticals Inc. | 2.7 Million USD | 416.978% |
| GeneThera, Inc. | - USD | Infinity% |
| Inhibitor Therapeutics, Inc. | -8.83 Million USD | 2.876% |
| AVAX Technologies, Inc. | -5.9 Million USD | -45.441% |
| Zenith Capital Corp. | 10.06 Thousand USD | 85411.129% |
| Genscript Biotech Corporation | -1.06 Billion USD | 99.191% |
| Ember Therapeutics, Inc. | 200.43 Thousand USD | 4383.603% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| Sigyn Therapeutics, Inc. | 2.38 Million USD | 459.832% |
| WPD Pharmaceuticals Inc. | 164.5 Thousand USD | 5318.992% |
| Cotinga Pharmaceuticals Inc. | -18.31 Thousand USD | -46770.357% |
| Kadimastem Ltd | -253.1 Thousand USD | -3292.194% |
| Helix BioMedix, Inc. | -2.57 Million USD | -234.07% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Reve Technologies, Inc. | 201.25 Thousand USD | 4366.108% |
| LadRx Corporation | -2.03 Million USD | -321.598% |
| Cell Source, Inc. | 9.23 Million USD | 193.0% |
| Regen BioPharma, Inc. | 635.16 Thousand USD | 1451.725% |
| NovAccess Global Inc. | 2.17 Million USD | 494.118% |
| Affymax, Inc. | -5.59 Million USD | -53.398% |
| Itoco Inc. | 228.3 Thousand USD | 3860.632% |
| Rasna Therapeutics, Inc. | 135.98 Thousand USD | 6413.534% |
| Pathfinder Cell Therapy, Inc. | 4.95 Million USD | 273.204% |
| Mobile Lads Corp. | 484.23 Thousand USD | 1873.058% |
| CytoDyn Inc. | 20.26 Million USD | 142.373% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| NDT Pharmaceuticals Inc. | -647.00 USD | -1326903.4% |
| NanoSphere Health Sciences Inc. | -9268.34 USD | -92534.841% |
| Alseres Pharmaceuticals, Inc. | 7.7 Million USD | 211.416% |
| SYBLEU INC | 473.71 Thousand USD | 1912.425% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 4.45 Million USD | 292.633% |
| International Stem Cell Corporation | 2.59 Million USD | 431.495% |
| Bioxytran, Inc. | 1.89 Million USD | 552.138% |
| GlobeImmune, Inc. | - USD | Infinity% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | 62.41 Thousand USD | 13856.288% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | 2.18 Million USD | 493.677% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | 3.43 Million USD | 350.021% |
| Adhera Therapeutics, Inc. | 8.55 Million USD | 200.382% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | 772.6 Thousand USD | 1211.265% |
| Innovation Pharmaceuticals Inc. | -1.25 Million USD | -586.857% |
| Neutra Corp. | 52.18 Thousand USD | 16551.821% |
| Windtree Therapeutics, Inc. | -2.48 Million USD | -244.946% |
| PureTech Health plc | -167.19 Million USD | 94.865% |
| Coeptis Therapeutics, Inc. | -244.9 Thousand USD | -3405.689% |
| IXICO plc | -4.44 Million USD | -93.172% |
| IntelGenx Technologies Corp. | 13.21 Million USD | 164.95% |
| Gelesis Holdings, Inc. | 54.85 Million USD | 115.653% |
| CSL Limited | 10.52 Billion USD | 100.082% |
| Cellectis S.A. | -43.81 Million USD | 80.406% |